Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06842121 · ClinicalTrials.gov registry record · Phase 1
A Bioequivalence Study Comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Inorganic Phosphate (Sodium Phosphates Injection, USP)
A Phase 1 study, sponsored by Baxter Healthcare Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT06842121 is a Phase 1 study that has completed, run by Baxter Healthcare Corporation. The registered enrollment target is 42 participants.
The verdict
NCT06842121, a Phase 1 study, has completed, sponsored by Baxter Healthcare Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This is a phase 1, prospective, single-center, randomized sequence, double-blind, 2-way crossover, relative bioavailability study in healthy adult subjects comparing Sodium Glycerophosphate Injection (SGP) to Sodium Phosphate Injection (NaP). In this study it is planned to randomize approximately 42 healthy male and female subjects. All study periods will be completed during a single residency, the overall duration of residency will be 11 days (10 nights).
Interventions
- DRUG Sodium Glycerophosphate Injection
- DRUG Sodium Phosphates Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2025-01-27 |
| Est. Completion | 2025-05-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06842121
The ClinicalTrials.gov registry entry for NCT06842121 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baxter Healthcare Corporation, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sodium Glycerophosphate Injection is the first listed.
NCT06842121 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06842121 about?
NCT06842121 is a clinical study titled "A Bioequivalence Study Comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Inorganic Phosphate (Sodium Phosphates Injection, USP)". This is a phase 1, prospective, single-center, randomized sequence, double-blind, 2-way crossover, relative bioavailability study in healthy adult subjects comparing Sodium Glycerophosphate Injection (SGP) to Sodium Phosphate Injection (NaP). In this study it is planned to randomize approximately 4...
What is the current status of trial NCT06842121?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2025-01-27. Estimated completion is 2025-05-22.
What interventions are being tested in trial NCT06842121?
The interventions under investigation include: Sodium Glycerophosphate Injection (DRUG), Sodium Phosphates Injection (DRUG).
Who is sponsoring clinical trial NCT06842121?
This trial is sponsored by Baxter Healthcare Corporation, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.